Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 5
1987 1
1988 6
1989 11
1990 7
1991 3
1992 7
1993 6
1994 4
1995 5
1996 4
1997 7
1998 9
1999 8
2000 6
2001 6
2002 13
2003 9
2004 7
2005 11
2006 16
2007 13
2008 33
2009 29
2010 30
2011 28
2012 33
2013 49
2014 68
2015 64
2016 46
2017 48
2018 49
2019 33
2020 36
2021 46
2022 27
2023 23
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

717 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial.
Ramgopal MN, Castagna A, Cazanave C, Diaz-Brito V, Dretler R, Oka S, Osiyemi O, Walmsley S, Sims J, Di Perri G, Sutton K, Sutherland-Phillips D, Berni A, Latham CL, Zhang F, D'Amico R, Pascual Bernáldez M, Van Solingen-Ristea R, Van Eygen V, Patel P, Chounta V, Spreen WR, Garges HP, Smith K, van Wyk J. Ramgopal MN, et al. Among authors: di perri g. Lancet HIV. 2023 Sep;10(9):e566-e577. doi: 10.1016/S2352-3018(23)00136-4. Epub 2023 Aug 8. Lancet HIV. 2023. PMID: 37567205 Clinical Trial.
Pillars of long-term antiretroviral therapy success.
Taramasso L, Andreoni M, Antinori A, Bandera A, Bonfanti P, Bonora S, Borderi M, Castagna A, Cattelan AM, Celesia BM, Cicalini S, Cingolani A, Cossarizza A, D'Arminio Monforte A, D'Ettorre G, Di Biagio A, Di Giambenedetto S, Di Perri G, Esposito V, Focà E, Gervasoni C, Gori A, Gianotti N, Guaraldi G, Gulminetti R, Lo Caputo S, Madeddu G, Maggi P, Marandola G, Marchetti GC, Mastroianni CM, Mussini C, Perno CF, Rizzardini G, Rusconi S, Santoro M, Sarmati L, Zazzi M, Maggiolo F. Taramasso L, et al. Among authors: di perri g. Pharmacol Res. 2023 Oct;196:106898. doi: 10.1016/j.phrs.2023.106898. Epub 2023 Aug 28. Pharmacol Res. 2023. PMID: 37648103 Free article. Review.
Re-defining tigecycline therapy.
De Rosa FG, Corcione S, Di Perri G, Scaglione F. De Rosa FG, et al. Among authors: di perri g. New Microbiol. 2015 Apr;38(2):121-36. Epub 2015 Apr 21. New Microbiol. 2015. PMID: 25915055 Free article. Review.
Tenofovir alafenamide revisited.
Di Perri G. Di Perri G. Infez Med. 2020 Dec 1;28(4):525-533. Infez Med. 2020. PMID: 33257626 Free article.
The clinical pharmacology of integrase inhibitors.
Di Perri G, Calcagno A, Trentalange A, Bonora S. Di Perri G, et al. Expert Rev Clin Pharmacol. 2019 Jan;12(1):31-44. doi: 10.1080/17512433.2019.1553615. Epub 2018 Dec 21. Expert Rev Clin Pharmacol. 2019. PMID: 30513008 Review.
Ageing with HIV: a multidisciplinary review.
Calcagno A, Nozza S, Muss C, Celesia BM, Carli F, Piconi S, De Socio GV, Cattelan AM, Orofino G, Ripamonti D, Riva A, Di Perri G. Calcagno A, et al. Among authors: di perri g. Infection. 2015 Oct;43(5):509-22. doi: 10.1007/s15010-015-0795-5. Epub 2015 May 19. Infection. 2015. PMID: 25987480 Review.
Pharmacogenetics of ribavirin-induced anemia in HCV patients.
D'Avolio A, Cusato J, De Nicolò A, Allegra S, Di Perri G. D'Avolio A, et al. Among authors: di perri g. Pharmacogenomics. 2016 Jun;17(8):925-41. doi: 10.2217/pgs.16.22. Epub 2016 Jun 1. Pharmacogenomics. 2016. PMID: 27248282 Review.
717 results